And Still They Come Over Troubled Waters: Can Asia’s Third-Generation EGFR Tyrosine Kinase Inhibitors (Furmonertinib, Aumolertinib, Rezivertinib, Limertinib, Befotertinib, SH-1028, and Lazertinib) Affect Global Treatment of EGFR+ NSCLC
Sally C. M. Lau, Sai‐Hong Ignatius Ou
Topics & Concepts
OsimertinibMedicineT790MHazard ratioInternal medicineOncologyTyrosine kinaseConfidence intervalnon-small cell lung cancer (NSCLC)Cancer researchLung cancerEpidermal growth factor receptorGefitinibCancerReceptorErlotinibA549 cellLung Cancer Treatments and MutationsColorectal Cancer Treatments and StudiesGastric Cancer Management and Outcomes